Previous 10 | Next 10 |
Shares of Viatris (NASDAQ: VTRS) were jumping 16.2% higher as of 11:56 a.m. ET on Monday. The big gain came after the company announced its third-quarter results and revealed plans for two acquisitions. Viatris reported Q3 revenue of $4.08 billion. This result was down 10% year ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock IAA (NYSE: IAA ) stock is climbing higher on Monday thanks to a massive acquisition deal with Ritchie Bros Auctioneers (NYSE: RBA ). Ritchie Bros have agreed to acquire IAA in a dea...
Viatris ( NASDAQ: VTRS ) added ~16% in the morning hours Monday to reach the highest level since June after the generic drugmaker announced its Q3 2022 financial results and Oyster Point Pharma ( OYST ) agreed to a buyout deal with the company. However, VIatris ( V...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Viatris (NASDAQ: VTRS ) issued a press release today with a slew of good news. For one thing, Viatris is acquiring two different businesses . Also, these acquisitions are expected to greatly enhance the company’...
Viatris Announces Two Acquisitions to Create What it Expects to be a Leading Ophthalmology Franchise; Plans to Provide Strategic Update on its February 2022 Investor Event PR Newswire Expects Biocon Biologics Transaction to Close Shortly Intends to Begin Exec...
Tender Offer to Acquire All Outstanding Shares of Oyster Point Pharma for $11.00 per Share, Plus a Contingent Value Right of Up To $2.00 per Share PRINCETON, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), (“Oyster Point Pharma”), ...
Viatris press release ( NASDAQ: VTRS ): Q3 GAAP EPS of $0.29 beats by $0.10 . Adj net earnings of $1.06B. Revenue of $4.07B (-10.0% Y/Y) misses by $70M . For further details see: Viatris GAAP EPS of $0.29 beats by $0.10, revenue of $4.07B misses by $70M ...
Viatris Reports Strong Third Quarter 2022 Results PR Newswire Reaffirms 2022 Guidance Ranges [1] Across Total Revenues, Adjusted EBITDA and Free Cash Flow; Driven by Solid Operating Momentum Despite Foreign Exchange Headwinds and Absorbing Inflation Impact to Date ...
Viatris ( NASDAQ: VTRS ) is scheduled to announce Q3 earnings results on Monday, November 7th, before market open. The consensus EPS Estimate is $0.84 and the consensus Revenue Estimate is $4.14B (-8.4% Y/Y). Over the last 1 year, VTRS has beaten EPS estimates 100%...
Gilead Sciences, Inc. ( NASDAQ: GILD ) shares have advanced from $61.45 to $80 since the beginning of October 2022, and the current price stands at $79.46. Gilead Sciences reported better-than-expected third-quarter results last week, and the company’s management updated ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-26 12:25:00 ET The late comedian Rodney Dangerfield was famous for his catchphrase, "I don't get no respect." Does Dangerfield's line apply to some stocks today? Absolutely. Three Motley Fool contributors think they've found surprisingly underrated pharmaceutical stocks to b...
NORTHAMPTON, MA / ACCESSWIRE / July 23, 2024 / No country can make every medicine people need, and no medicine is made in every country. If a country or region relies on supply only from within their region and they experience a crisis, there is a risk people won't get the medicines they need, w...
NORTHAMPTON, MA / ACCESSWIRE / July 18, 2024 / Viatris is a global healthcare company focused on bringing high-quality medicines to patients through a hybrid approach that bridges the traditional divide between generics and brands, combining the best of both, to more holistically address healthc...